Team:UC Davis/Project
From 2009.igem.org
Line 13: | Line 13: | ||
</b><b style="color: rgb(255, 255, 153);"><span | </b><b style="color: rgb(255, 255, 153);"><span | ||
style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | ||
- | href="https://2009.igem.org/Team:UC_Davis | + | href="https://2009.igem.org/Team:UC_Davis"><img alt="" |
src="https://static.igem.org/mediawiki/2009/a/a4/UCDAVIS_PIC3.png" | src="https://static.igem.org/mediawiki/2009/a/a4/UCDAVIS_PIC3.png" | ||
style="border: 0px solid ; width: 83px; height: 36px;"></a> </big></big></big></big></span></b><a | style="border: 0px solid ; width: 83px; height: 36px;"></a> </big></big></big></big></span></b><a | ||
- | href="https://2009.igem.org/Team:UC_Davis/ | + | href="https://2009.igem.org/Team:UC_Davis/About_Us"><b |
style="color: rgb(255, 255, 153);"><span | style="color: rgb(255, 255, 153);"><span | ||
style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><img | style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><img | ||
Line 27: | Line 27: | ||
</big></big></big></big></span></b><b style="color: rgb(255, 255, 153);"><span | </big></big></big></big></span></b><b style="color: rgb(255, 255, 153);"><span | ||
style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | ||
- | href="https://2009.igem.org/Team:UC_Davis/ | + | href="https://2009.igem.org/Team:UC_Davis/Project"><img alt="" |
src="https://static.igem.org/mediawiki/2009/b/b9/UCDAVIS_PIC8.png" | src="https://static.igem.org/mediawiki/2009/b/b9/UCDAVIS_PIC8.png" | ||
style="border: 0px solid ; width: 78px; height: 36px;"></a> </big></big></big></big></span></b><b | style="border: 0px solid ; width: 78px; height: 36px;"></a> </big></big></big></big></span></b><b | ||
style="color: rgb(255, 255, 153);"><span | style="color: rgb(255, 255, 153);"><span | ||
style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | ||
- | href="https://2009.igem.org/Team:UC_Davis/ | + | href="https://2009.igem.org/Team:UC_Davis/Notebook"><img alt="" |
src="https://static.igem.org/mediawiki/2009/2/2f/UCDAVIS_PIC5.png" | src="https://static.igem.org/mediawiki/2009/2/2f/UCDAVIS_PIC5.png" | ||
style="border: 0px solid ; width: 81px; height: 36px;"></a> </big></big></big></big></span></b><b | style="border: 0px solid ; width: 81px; height: 36px;"></a> </big></big></big></big></span></b><b | ||
Line 39: | Line 39: | ||
style="color: rgb(255, 255, 153);"><span | style="color: rgb(255, 255, 153);"><span | ||
style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | style="font-size: 13.5pt; font-family: "Times New Roman","serif";"><big><big><big><big><a | ||
- | href="https://2009.igem.org/Team:UC_Davis/ | + | href="https://2009.igem.org/Team:UC_Davis/Parts"><img alt="" |
src="https://static.igem.org/mediawiki/2009/a/a6/UCDAVIS_PIC6.png" | src="https://static.igem.org/mediawiki/2009/a/a6/UCDAVIS_PIC6.png" | ||
style="border: 0px solid ; width: 78px; height: 37px;"></a> <a | style="border: 0px solid ; width: 78px; height: 37px;"></a> <a | ||
- | href="https://2009.igem.org/Team:UC_Davis/ | + | href="https://2009.igem.org/Team:UC_Davis/Contacts_References"><img alt="" |
src="https://static.igem.org/mediawiki/2009/1/1d/UCDAVIS_PIC7.png" | src="https://static.igem.org/mediawiki/2009/1/1d/UCDAVIS_PIC7.png" | ||
style="border: 0px solid ; width: 83px; height: 37px;"></a></big></big></big></big></span></b><b | style="border: 0px solid ; width: 83px; height: 37px;"></a></big></big></big></big></span></b><b |
Revision as of 01:46, 26 September 2009
Celiac Disease:
What is Celiac Disease?
Celiac Disease is a form of autoimmune disorder, which occurs inside the small intestine. When the body cannot digest gliadin (component of gluten) properly, this leads to an immune response (14). Furthermore, different people have different reactions to these immune responds such as pain and vomiting (14). It has been estimated that about one out of 133 Americans are currently suffering from this disease (11); including one of our teammate's friends, and that was what sparked our interest in designing this project.
What happens in the normal small intestine?
In the normal small intestine, the Brush border membrane lets small peptides and molecules like water through and into the bloodstream. The brush border membrane also lets larger molecules into the blood stream, similar to Gliadin; however, these larger molecules are converted through a transcellular route, which does not prompt an immune system response.
What happens in celiac disease small intestine?
The Brush border membrane in the small intestine of people suffering from Celiac Disease allows large molecules such as gliadin to go straight into the blood stream without directing them through the transcellular route. Once gliadin passes through, Antigen Presenting Cells (APCs) recognize gliadin as a foreign object and will attack. This immune response causes pain and other adverse side-effects.
The
immune response not only causes abdominal bloating, pain, weight loss
and
vomiting, most of the time it may also damage intestinal villi, which
are
important for absorbing nutrition. The destruction of villi eventually
leads to
a lack of absorption of different nutrients, which can lead to other
illnesses
(14). Some people affected with this disorder can also suffer from autoimmune
thyroid disease, autoimmune liver disease, rheumatoid arthritis (diseases
in which body immune system attacks healthy cells/tissues)
(14).
Currently,
no cure has been found
for this illness. The only way to avoid some of celiac disease’s
symptoms is by
adopting a gluten free diet (14, 12, and 11). However, you are more
likely to
find gluten in your everyday diet. Therefore, avoiding gluten is not
easy or
pleasant from a gastronomical standpoint.
Nevertheless, over the past years, researchers have discovered an
enzyme from Aspergillus
niger, a newly identified prolyl endoprotease, that was observed to
"work optimally at 4-5pH and remains stable at 2pH"(8) and maybe this
enzyme will lead us to an alternative treatment for this disorder (8).
Studies
have shown that prolyl-endoprotease from Aspergillus niger is
able to
"degrade gluten in vitro and under conditions similar to the ones
present
in the gastrointestinal tract." (8) ; but due to licensing restrictions
we
have opted not to work with this protein.
Recently (year 2007), a study has suggested an alternative approach by
combining a glutamine-specific endoprotease (EP-B2 from barley) and a
prolyl
endopeptidase (SC PEP from Sphingomonas capsulata); with gastric
activity and
complementary substrate specificity there is a possibility of
increasing the
safe threshold of ingested gluten (12). One of the advantages of this
“combination product is that both enzymes are active and stable in
stomach and
can therefore be administered as lyophilized powders or simple capsules
or
tablets” (12).
Note:
Moreover, this study was first
“evaluated via in vitro digestion of whole-wheat beard and then
confirmed by in
vivo studies in rats (12), unlike other earlier studies which were
performed on
synthetic gluten oligopeptides, recombinant gliadin proteins, or
uncooked
gluten” (12).
Our approach:
We
are going to break down gluten inside the stomach (before it arrives to
the
small intestine), because gliadin does not prompt an immune system
response until
it is absorbed in the small intestine.
Another worry is a spread of our synthetic bug, so we engineered
a
‘safety-switch’ via induction of cell death through a pH sensor system. Due to the change of pH from the stomach to
the small intestine, our pH system is induced; cell death, thus
limiting our
bug to the stomach.
The
advantages of our model are, that unlike other suggested treatments
which
require consuming capsules or tablets rapidly, by using Escherichia coli as
our model chassis for this project: we can lower the number of times
which this
‘cure’ needs to be consumed thus making it less troublesome, costly,
and more
convenient.
Our project is
split into two parts:
1.Induced Secretion
- Gene sequence for secretion system
- Adding secretion
- Assay for measuring protein localization and activity
- Finding an appropriate biological pH sensor
- Wiring the pH sensor into our system
- Assay for measuring the behavior of the pH sensor